← Leaderboards
Dianna Ammons Johnson
University Of Tennessee Health Sci Ctr
$4,714,453
Attributed
$4,714,453
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,374,739 · 8
By mechanism
P30$4,889,626 · 3
R44$2,081,932 · 1
R43$1,111,157 · 3
R01$292,024 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Monica M Jablonski$8,426,014
- Tonia S Rex$6,360,522
- Mark S Ledoux$5,875,232
- Jonathan H Jaggar$20,198,511
- Alessandro Iannaccone$2,294,146
Others in their field
Top investigators on “Vision”
- Chanza Baytop · Westat, Inc.$271,217,917
- Edward W Maly · United Nations Children'S Fund$264,005,699
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Everette D Joseph · Howard University$243,972,016
Research focus
VisionEyedropsBlindnessPreparationSmall Business Innovation Research GrantTopical ApplicationRisk FactorsPharmaceutical PreparationsVisual FieldsPregabalinFormulationFda ApprovedGlaucomaStandard Of CarePropertyPhysiologic Intraocular PressureDoseSide EffectBiomedical FacilityAffectPreservationEngineeringAdultInnovation
Grant awards (29)
Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation$1,015,754
R44 · FY2025 · EY · contact PI
Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation$1,066,178
R44 · FY2024 · EY · contact PI
Development of a novel depot delivery system for a glaucoma therapeutic$81,745
R43 · FY2024 · EY · contact PI
Development of a novel depot delivery system for a glaucoma therapeutic$56,864
R43 · FY2024 · EY · contact PI
Development of a novel depot delivery system for a glaucoma therapeutic$336,047
R43 · FY2023 · EY · contact PI
Neuroprotective Properties of a Novel Glaucoma Drug and Formulation$356,501
R43 · FY2021 · EY · contact PI
Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma$55,000
R43 · FY2020 · EY · contact PI
Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma$225,000
R43 · FY2019 · EY · contact PI
CORE GRANT FOR VISION RESEARCH$124,911
P30 · FY2010 · EY · contact PI
CORE GRANT FOR VISION RESEARCH$382,720
P30 · FY2009 · EY · contact PI
CORE--IMAGING$190,952
P30 · FY2009 · EY · contact PI
CORE GRANT FOR VISION RESEARCH$375,484
P30 · FY2008 · EY · contact PI
CORE--IMAGING$187,342
P30 · FY2008 · EY · contact PI
CORE GRANT FOR VISION RESEARCH$368,457
P30 · FY2007 · EY · contact PI
CORE--IMAGING$183,836
P30 · FY2007 · EY · contact PI
CORE GRANT FOR VISION RESEARCH$361,641
P30 · FY2006 · EY · contact PI
CORE--IMAGING$155,233
P30 · FY2006 · EY · contact PI
CORE GRANT FOR VISION RESEARCH$884,619
P30 · FY2005 · EY
CORE--IMAGING$462,390
P30 · FY2005 · EY
ADMINISTRAION$49,587
P30 · FY2005 · EY
CORE GRANT FOR VISION RESEARCH$189,715
P30 · FY2004 · EY
CORE GRANT FOR VISION RESEARCH$184,190
P30 · FY2003 · EY
CORE GRANT FOR VISION RESEARCH$178,824
P30 · FY2002 · EY
BIOCHEMICAL ANALYSIS OF NEUROTRANSMITTERS$69,688
R01 · FY2002 · EY
CORE--IMAGING MODULE$0
P30 · FY2002 · EY
CORE GRANT FOR VISION RESEARCH$168,560
P30 · FY2001 · EY
CORE--IMAGING MODULE$0
P30 · FY2001 · EY
CORE GRANT FOR VISION RESEARCH$441,165
P30 · FY2000 · EY
BIOCHEMICAL ANALYSIS OF NEUROTRANSMITTERS$222,336
R01 · FY2000 · EY